Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Prevalence, risk factors and clinical characteristics in patients with genotype 6 chronic hepatitis C: a single institute experience

Authors
Shin S.K.Park S.Y.Jung Y.K.Kim E.J.Lee H.N.Lee J.J.Kwon O.S.Choi D.J.Kim Y.S.Kim J.H.
Issue Date
2015
Citation
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, v.65, no.2, pp.105 - 111
Indexed
SCOPUS
KCI
Journal Title
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume
65
Number
2
Start Page
105
End Page
111
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/8392
DOI
10.4166/kjg.2015.65.2.105
ISSN
1598-9992
Abstract
BACKGROUND/AIMS: Hepatitis C genotypes 1 and 2 are widely distributed globally. In contrast, genotype 6 is found mainly in Southeast Asia, while genotype 6 is rare in Korea. This study aims to investigate the prevalence, risk factors and clinical characteristics of patients with genotype 6 chronic hepatitis C.METHODS: We retrospectively identified 133 HCV-infected patients who underwent HCV genotype analysis between January 2012 and December 2012, and analyzed the prevalence, risk factors and clinical characteristics of patients diagnosed with genotype 6 chronic hepatitis C.RESULTS: Among 133 patients, 53 patients (39.8%) were infected with genotype 1, 62 patients (46.6%) with genotype 2, 2 patients (1.5%) with genotype 3, 14 patients (10.5%) with genotype 6, and 2 patients (1.5%) with mixed genotypes (genotype 1 and 6). The risk factors associated with genotype 6 were acupuncture (n=4, 28.6%), intravenous drug use (n=3, 21.4%), tattoo (n=2, 14.3%), and transfusion (n=2, 14.3%). Of the 14 patients with genotype 6, 6 patients were treated with pegylated interferon and ribavirin. Five patients had reached the end of treatment. All patients reaching end of treatment for genotype 6 showed early virological response and sustained virological response.CONCLUSIONS: The prevalence of genotype 6 is 10.5% and mixed infections of genotype 1 and 6 are 1.5% in patients with chronic hepatitis C. A major potential risk factor is intravenous drug use and the treatment response rate to pegylated interferon plus ribavirin is high in patients with genotype 6 chronic hepatitis C. Large scale multicenter studies are needed.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Jung, Young Kul photo

Jung, Young Kul
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE